Get Clarity, Not Just Headlines.
Get Started
SubscribeLogin
Israel-Hamas Conflict
Cannes Film Festival
Donald Trump
Social Media
Artificial Intelligence
European Union
Nature
Taxes
Natural Disasters
Soccer
Education
Immigration
Netflix
Published • loading... • Updated

Frontline Belrestotug Plus Dostarlimab Misses PFS End Point in PD-L1–High NSCLC

Summary by onclive.com
Belrestotug plus dostarlimab did not improve PFS vs dostarlimab monotherapy in PD-L1–high NSCLC, supporting the termination of belrestotug development.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

3 Articles

All
Left
Center
Right
GeneOnline NewsGeneOnline News

Belrestotug Data Presented at ESMO 2024 Conference

Recent data regarding belrestotug emerged following a p […] The post Belrestotug Data Presented at ESMO 2024 Conference first appeared on GeneOnline News. The post Belrestotug Data Presented at ESMO 2024 Conference appeared first on GeneOnline News.

Read Full Article
targetedonc.comtargetedonc.com

Frontline Dato-DXd Looks Promising in NSCLC

Findings from the TROPION-Lung04 study were presented at the ESMO Targeted Anticancer Therapies Congress 2025 in March.

Read Full Article
onclive.comonclive.com

Frontline Belrestotug Plus Dostarlimab Misses PFS End Point in PD-L1–High NSCLC

Belrestotug plus dostarlimab did not improve PFS vs dostarlimab monotherapy in PD-L1–high NSCLC, supporting the termination of belrestotug development.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

onclive.com broke the news in on Tuesday, May 13, 2025.
Sources are mostly out of (0)

Similar News Topics

News
For You
SearchBlindspotLocal